regulator of chromosome condensation 2 pseudogene 6Genealiases: []
Q-omics provides the consensus-scored RCC2P6 profile across patient tissues and cancer cell-line models. RCC2P6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RCC2P6 is differentially expressed in 13, with the highest sampling consensus in STAD. Additionally, RCC2P6 RNA expression shows 17,730 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, STAD, and KIRP as cancer lineages where RCC2P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RCC2P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RCC2P6 survival associations across molecular data types. RCC2P6 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RCC2P6 RNA expression–survival associations across cancer types. High RCC2P6 expression shows unfavorable associations in LGG, but favorable associations in UCEC, KIRC, READ, CESC and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RCC2P6 RNA expression.
This table summarizes RCC2P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RCC2P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RCC2P6 shows lower tumor expression in KICH and higher tumor expression in STAD, COAD, BLCA, LIHC and UCEC. The STAD box plot shows higher RCC2P6 RNA expression in tumor versus normal tissue (log2 FC = +0.460, t-test p < 0.001).
This table shows molecular features associated with RCC2P6 in patient tissues and cancer cell lines. In patient samples, RCC2P6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
